Zusammenfassung (Niederländisch oder Französisch oder Englisch)
| TRIAL DESCRIPTION | |
|---|---|
| Title | KCE-201257: Behandlung für stotternde Kinder im Vorschulalter: eine randomisierte, multizentrische, nicht unterlegene pragmatische Parallelgruppenstudie mit Mini-KIDS, sozialer kognitiver Verhaltenstherapie und dem Lidcombe-Programm - TreatPaCS |
|
Participants (P) |
Preschool age children treated by stuttering specialists in private practice settings. Parents are always intensively involved in treatment. |
|
Intervention (I) |
Mini-KIDS is a direct treatment based on principles of stuttering modification, with pseudo-stuttering, that is, deliberate stuttering, as one of the main components. The program for 4-6-year old children consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old children does not include stage 3 because of metacognitive development at that age. Speech-Language Therapist (SLT) and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech. Later on in treatment and if necessary, children learn to recognise and alter their stuttering moments. |
|
Control (C) |
The LP is an operant program that directly provides verbal feedback to the child’s stutter-free speech (mainly) and the child’s stuttering (occasionally). The program comprises two stages: Stage 1 in which (near) zero levels of stuttering are achieved and Stage 2 in which the achieved (near) zero levels of stuttering are maintained for a long period of time. The LP usually takes between 11 to 23 (60-minute) treatment sessions to achieve the goals of Stage 1, i.e. (near) zero levels of stuttering. |
|
Outcome (O) |
Primary outcome: Percentage Syllables Stuttered (%SS, measured in videorecorded speech samples) at 18-months post-randomisation. |
|
Trial Design |
A three arm 1:1:1 randomised, multicentre, open-label non-inferiority parallel group pragmatic trial |
|
Sample Size |
249 |
|
Trial duration |
47 months |
|
First Patient In |
01/04/2022 |
| Trial Report | 01/03/2026 |
|
Budget |
1 890 000 euro |
|
Sponsor |
Thomas More Mechelen-Antwerpen vzw |
|
Chief Investigator |
Sabine Van Eerdenbrugh |
|
External Partners |
UZA |
|
Number of Participating sites |
+/- 30 |
Clinicaltrials.gov: NCT05185726
Webpage: